Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Toxicity of Subcutaneous Ketamine in the Management of Cancer Pain

被引:166
作者
Hardy, Janet [1 ]
Quinn, Stephen [2 ]
Fazekas, Belinda [2 ]
Plummer, John [3 ]
Eckermann, Simon [4 ]
Agar, Meera [6 ,7 ]
Spruyt, Odette [5 ]
Rowett, Debra [2 ]
Currow, David C. [2 ]
机构
[1] Mater Hlth Serv, Brisbane, Qld, Australia
[2] Flinders Univ S Australia, Adelaide, SA, Australia
[3] Flinders Med Ctr, Bedford Pk, SA, Australia
[4] Univ Wollongong, Australian Hlth Serv Res Inst, Wollongong, NSW 2522, Australia
[5] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[6] Braeside Hammond Care, Sydney, NSW, Australia
[7] SW Sydney Local Hlth Dist, Sydney, NSW, Australia
关键词
PALLIATIVE CARE; NEUROPATHIC PAIN; CLINICAL-TRIALS; SCALE;
D O I
10.1200/JCO.2012.42.1081
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The anesthetic ketamine is widely used for pain related to cancer, but the evidence to support its use in this setting is weak. This study aimed to determine whether ketamine is more effective than placebo when used in conjunction with opioids and standard adjuvant therapy in the management of chronic uncontrolled cancer pain. Ketamine would be considered of net benefit if it provided clinically relevant improvement in pain with limited breakthrough analgesia and acceptable toxicity. Patients and Methods In this multisite, dose-escalation, double-blind, randomized, placebo-controlled phase III trial, ketamine or placebo was delivered subcutaneously over 3 to 5 days. Results In all, 185 participants were included in the primary analysis. There was no significant difference between the proportion of positive outcomes (0.04; 95% CI, -0.10 to 0.18; P = .55) in the placebo and intervention arms (response rates, 27% [25 of 92] and 31% [29 of 93]). Pain type (nociceptive v neuropathic) was not a predictor of response. There was almost twice the incidence of adverse events worse than baseline in the ketamine group after day 1 (incidence rate ratio, 1.95; 95% CI, 1.46 to 2.61; P < .001) and throughout the study. Those receiving ketamine were more likely to experience a more severe grade of adverse event per day (odds ratio, 1.09; 95% CI, 1.00 to 1.18; P = .039). The number of patients needed to treat for one additional patient to have a positive outcome from ketamine was 25 (95% CI, six to infinity). The number needed to harm, because of toxicity-related withdrawal, was six (95% CI, four to 13). Conclusion Ketamine does not have net clinical benefit when used as an adjunct to opioids and standard coanalgesics in cancer pain. J Clin Oncol 30: 3611-3617. (C) 2012 by American Society of Clinical Oncology
引用
收藏
页码:3611 / 3617
页数:7
相关论文
共 26 条
[1]   Evidence in palliative care research: how should it be gathered? [J].
Aoun, SM ;
Kristjanson, LJ .
MEDICAL JOURNAL OF AUSTRALIA, 2005, 183 (05) :264-266
[2]  
BELL R, 2003, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD003351
[3]   Ketamine as aduvant to opioids for cancer pain. A qualitative systematic review [J].
Bell, RF ;
Eccleston, C ;
Kalso, E .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2003, 26 (03) :867-875
[4]   The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs [J].
Bennett, M .
PAIN, 2001, 92 (1-2) :147-157
[5]   Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS) [J].
Bremner, JD ;
Krystal, JH ;
Putnam, FW ;
Southwick, SM ;
Marmar, C ;
Charney, DS ;
Mazure, CM .
JOURNAL OF TRAUMATIC STRESS, 1998, 11 (01) :125-136
[6]  
Cancer therapy evaluation program, COMM TERM CRIT ADV E
[7]  
Cleeland CS., 1989, ADV PAIN RES THER, V12, p391?03
[8]   Prescribing in palliative care as death approaches [J].
Currow, David C. ;
Stevenson, James P. ;
Abernethy, Amy P. ;
Plummer, John ;
Shelby-James, Tania M. .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2007, 55 (04) :590-595
[9]   Defining Refractory Pain in Cancer for Clinicians and Researchers [J].
Currow, David C. ;
Spruyt, Odette ;
Hardy, Janet .
JOURNAL OF PALLIATIVE MEDICINE, 2012, 15 (01) :5-6
[10]   Planning phase III multi-site clinical trials in palliative care: the role of consecutive cohort audits to identify potential participant populations [J].
Currow, David Christopher ;
Shelby-James, Tania M. ;
Agar, Meera ;
Plummer, John ;
Rowett, Deborah ;
Glare, Paul ;
Spruyt, Odette ;
Hardy, Janet .
SUPPORTIVE CARE IN CANCER, 2010, 18 (12) :1571-1579